TY - JOUR
AU1 - Wright, Peter F.
AU2 - Dolin, Raphael
AU3 - La Montagne, John R.
AB - THE JOUR:\AL OF I:\FECTIOUS DISEASES. VOL. 134, :\0. 6 • December 1976 © 1976 by the University of Chicago. All rights reserved. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration Summary of Clinical Trials of Influenza Vaccines-II Two previous reports have been made related to Based on the serologic response and reactogenicity the National Influenza Immunization Program in the single-dose trials, graded high doses of split­ [1, 2]. The second report [2J summarized data de­ product vaccine and low doses of whole-virus vac­ rived from testing of the vaccines from four man­ cine were employed. The investigators participat­ ufacturers in >5,000 volunteers aged three to 100 i ng in these trials were sponsored by the N a tion­ al Institute of Allergy and Infectious Diseases years. The completion of this round of tests en­ abled issuance of recommendations for immuni­ (NIAJD) under the National Influenza Immuni­ zation of adults 18 years of age or older. Antibody zation Program.' Studies were performed in ap­ proximately 1,300 normal or high-risk individuals responses in persons 25 years or older 
TI - Summary of Clinical Trials of Influenza Vaccines-II
JF - The Journal of Infectious Diseases
DO - 10.1093/infdis/134.6.633
DA - 1976-12-01
UR - https://www.deepdyve.com/lp/oxford-university-press/summary-of-clinical-trials-of-influenza-vaccines-ii-QaXfIX5f1p
SP - 633
EP - 638
VL - 134
IS - 6
DP - DeepDyve
ER -